Observe Medical (OBSRV) Trading update summary

Strategic vision and business model

• Focus on developing proprietary products under own trademarks and building a scalable Nordic medtech platform with global reach, emphasizing profitable growth, product development, and regulatory performance.

• Commercialization and portfolio development leverage a Nordic ecosystem for innovation and global distribution.

• Aims to improve patient welfare, health economics, and data accuracy through advanced solutions.

Product development and innovation

• Successfully launched UnoMeter Safeti Max, now commercially available after positive clinical study and CE certification.

• Safeti Max incorporates SafeCoat technology, with three patents, one pending, and UnoSafeCoat trademark registered.

• Portfolio expanded from two/three to seven products in 1.5 years, including new front-mounted UnoMeter and US-style products.

• Sippi remains a strategic focus, targeting ICU digital measurement market, with CE certification and market launch planned when portfolio traction is sufficient.

Financial and trading update

• Achieved 80% year-on-year sales growth, reaching NOK 22 million in the last twelve months, with Q1 2026 sales estimated at NOK 7.6 million, a 60% YoY increase.

• Quarterly order intake grew 73% to NOK 8.5 million, reflecting improved market penetration and activity.

• UnoMeter Safeti Plus is a key driver of sales momentum.

• On track to become cash positive within the year.